The use of digital biomarkers has the potential to streamline the diagnostic workflow in dementia practice, tackling the bottleneck created by a lack of specialized services. Digital biomarker platforms, such as the Altoida Digital Neuro Signature, are easy to implement and could be used to screen patients prior to referral for further confirmatory testing. M. Florencia Iulita, PhD, Altoida, Inc., describes the progress made in this space, as well as ongoing efforts to optimize and validate the Altoida assessment for clinical use. The algorithm-based software uses augmented reality tasks, motoric function tests, and speech tasks to evaluate motor, visual, perceptual, and memory function. Beyond clinical practice, researchers are also beginning to use digital biomarkers as exploratory endpoints in trials, to aid in efficacy assessments of investigational agents. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
